Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic Equivalence of Orlistat 60 mg in Healthy Adults
NCT05076474Phase 1Completed
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Oct 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of orlistat in obesity (3 arms), sponsored by Shandong New Time Pharmaceutical. Primary endpoint: Fecal fat excretion over 24 hours at 3 days. Started Oct 2020; status: completed.
02
Drugs
orlistat
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05076474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076474.